what do we know about the dying process? - the marie curie ... coyle - what do we know about...

1
www.mcpcil.org.uk What do we know about the dying process? The biology of dying – a systematic review Séamus Coyle 1 , Rachael McDonald 2 , Amara Nwosu 1 , Richard Latten 1 , Stephen Mason 1 , John Ellershaw 1 1 Marie Curie Palliative Care Institute Liverpool, University of Liverpool 2 Southport Hospital 1 Neuberger, J. (2013). More care, less pathway: a review of the Liverpool Care Pathway. U. Department of Health. 2 Perry EK, Perry RH, Tomlinson BE. The influence of agonal status on some neurochemical activities of postmortem human brain tissue. Neurosci Lett. 1982 Apr 26;29(3):303-7. 3 Kadhim H, Deltenre P, Segers V, Sébire G. Selective expression of a neuromodulatory cytokine (IL-2) in specific brainstem neurovegetative centers: a possible final common neuro-molecular pathway in dying patients. Med Hypotheses. 2012 Jun;78(6):793-5. doi: 10.1016/ j.mehy.2012.03.010. Epub 2012 Apr 11. 4 Kadhim H, Deltenre P, De Prez C, Sébire G. Interleukin-2 as a neuromodulator possibly implicated in the physiopathology of sudden infant death syndrome. Neurosci Lett. 2010 Aug 16;480(2): 122-6. CONCLUSION BACKGROUND Diagnosing when a patient with advanced disease is in the last months, weeks, days of their life is an ongoing difficulty for the medical teams involved in their care. There are no precise ways of telling accurately when a patient is in the last days of life 1 . Thus there is often significant clinical uncertainty towards the end of a patient’s life. METHODS A systematic review of the biology of dying was performed following PRISMA guidelines. Titles and abstracts from each database were examined independently for relevance. Two search strategies were performed: Search strategy 1 (Death OR Dying) AND (biolog* OR physiol* OR patho* OR pathophysiol*) Search strategy 2 (terminal*, Terminal*) AND (patient* OR Patient*) AND (biolog* OR physiol* OR patho* OR pathophysiol*) Our search strategy included a systematic search of databases (EMBASE and MEDLINE) and hand searching of reference and citation lists of relevant papers. 2322 articles on MEDLINE and 3016 articles from EMBASE were identified. DISCUSSION AIMS To review the literature to assess the knowledge of the biology of dying – except sudden death. Although a number of papers describe a process of dying, it is evident from the review that incredibly little is known about the biology of dying. There were no prospective studies investigating biochemical changes during dying. Perry et al 2 investigated brain biochemical activities in relation to agonal status in order to establish if agonal status affected neurochemical activities in general, and if suitable ‘chemical markers’ of the pre terminal or terminal state could be identified. Cases were divided into those dying after a period of normal or near normal health Category A - where death occurred relatively quickly e.g. due to ischaemic heart disease and Category B, those dying after a prolonged period of severe illness including bronchopneumonia, renal and hepatic failure, which frequently terminated in coma. 23 neurochemicals and 13 amino acids were investigated. Contrasted with Category A, patients in Category B showed highly significant reductions in glutamate decarboxylase, phosphofructokinase and tissue pH and increases in the amino acids phenylalanine, lysine, leucine, and most extensively in tryptophan. Kadhim et al 3 have shown in autopsy studies that Interleukin-2 (IL-2) is preferentially expressed in brainstem neuronal centres implicated in cardio-respiratory control mechanisms in critically ill aging adults 3 as well as young infant patients 4 who died from various conditions. However, the adult sample size was very small (n=2). A number of core themes within the literature were identified. These can be classified as: Prognostication Common terminal symptoms (cachexia, anorexia, fatigue, dyspnoea, terminal secretions, delerium, agitation and dehydration) Signs of death in the last 2 weeks of life Postmortem studies including causes of death Animal studies of terminal senescence Titles and Abstracts recovered from Search 1 MEDLINE (n=699) EMBASE (n=819) Titles and Abstracts for consideration (n=5348) Titles and Abstracts deemed not related to the research question (n=5241) Titles and Abstracts reviewed (n=107) Relevant Articles (n=3) Titles and Abstracts recovered from Search 2 MEDLINE (n=1623) EMBASE (n=2197) No Duplicates were removed SYSTEMATIC REVIEW FLOW CHART REFERENCES 1. There are few studies investigating the biological changes during dying and there are no studies prospectively investigating biochemical changes during the dying process. 2. A number of authors postulate a common final dying pathway. 3. Research into the biological changes at the end of life could develop a greater understanding of the dying process. This research would have the potential to significantly impact the care future dying patients receive.

Upload: lethuan

Post on 01-Apr-2019

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: What do we know about the dying process? - The Marie Curie ... coyle - what do we know about the... · What do we know about the dying process? ... illness including bronchopneumonia,

www.mcpcil.org.uk

What do we know about the dying process? The biology of dying – a systematic reviewSéamus Coyle1, Rachael McDonald2, Amara Nwosu1, Richard Latten1, Stephen Mason1, John Ellershaw1

1Marie Curie Palliative Care Institute Liverpool, University of Liverpool 2Southport Hospital

1 Neuberger, J. (2013). More care, less pathway: a review of the Liverpool Care Pathway. U. Department of Health.

2 Perry EK, Perry RH, Tomlinson BE. The influence of agonal status on some neurochemical activities of postmortem human brain tissue. Neurosci Lett. 1982 Apr 26;29(3):303-7.

3 Kadhim H, Deltenre P, Segers V, Sébire G. Selective expression of a neuromodulatory cytokine (IL-2) in specific brainstem neurovegetative centers: a possible final common neuro-molecular pathway in dying patients. Med Hypotheses. 2012 Jun;78(6):793-5. doi: 10.1016/ j.mehy.2012.03.010. Epub 2012 Apr 11.

4 Kadhim H, Deltenre P, De Prez C, Sébire G. Interleukin-2 as a neuromodulator possibly implicated in the physiopathology of sudden infant death syndrome. Neurosci Lett. 2010 Aug 16;480(2): 122-6.

CONCLUSION

BACKGROUND

Diagnosing when a patient with advanced disease is in the last months, weeks, days of their life is an ongoing difficulty for the medical teams involved in their care. There are no precise ways of telling accurately when a patient is in the last days of life1. Thus there is often significant clinical uncertainty towards the end of a patient’s life.

METHODS

A systematic review of the biology of dying was performed following PRISMA guidelines. Titles and abstracts from each database were examined independently for relevance. Two search strategies were performed:

Search strategy 1(Death OR Dying) AND (biolog* OR physiol* OR patho* OR pathophysiol*)

Search strategy 2(terminal*, Terminal*) AND (patient* OR Patient*) AND (biolog* OR physiol* OR patho* OR pathophysiol*)

Our search strategy included a systematic search of databases (EMBASE and MEDLINE) and hand searching of reference and citation lists of relevant papers. 2322 articles on MEDLINE and 3016 articles from EMBASE were identified.

DISCUSSION

AIMS

To review the literature to assess the knowledge of the biology of dying – except sudden death.

Although a number of papers describe a process of dying, it is evident from the review that incredibly little is known about the biology of dying. There were no prospective studies investigating biochemical changes during dying.

Perry et al2 investigated brain biochemical activities in relation to agonal status in order to establish if agonal status affected neurochemical activities in general, and if suitable ‘chemical markers’ of the pre terminal or terminal state could be identified. Cases were divided into those dying after a period of normal or near normal health Category A - where death occurred relatively quickly e.g. due to ischaemic heart disease and Category B, those dying after a prolonged period of severe illness including bronchopneumonia, renal and hepatic failure, which frequently terminated in coma. 23 neurochemicals and 13 amino acids were investigated. Contrasted with Category A, patients in Category B showed highly significant reductions in glutamate decarboxylase, phosphofructokinase and tissue pH and increases in the amino acids phenylalanine, lysine, leucine, and most extensively in tryptophan.

Kadhim et al3 have shown in autopsy studies that Interleukin-2 (IL-2) is preferentially expressed in brainstem neuronal centres implicated in cardio-respiratory control mechanisms in critically ill aging adults3

as well as young infant patients4 who died from various conditions. However, the adult sample size was very small (n=2).

A number of core themes within the literature were identified. These can be classified as:

• Prognostication • Commonterminalsymptoms(cachexia,anorexia, fatigue, dyspnoea, terminal secretions, delerium, agitation and dehydration) • Signsofdeathinthelast2weeksoflife • Postmortemstudiesincludingcausesofdeath • AnimalstudiesofterminalsenescenceTitles and Abstracts

recovered from Search 1MEDLINE (n=699)EMBASE (n=819)

Titles and Abstractsfor consideration

(n=5348)

Titles and Abstracts deemed not related to the research question

(n=5241)

Titles and Abstractsreviewed(n=107)

Relevant Articles(n=3)

Titles and Abstractsrecovered from Search 2MEDLINE (n=1623)EMBASE (n=2197)

No Duplicates were removed

��

SYSTEMATIC REVIEW FLOW CHART

REFERENCES

1. There are few studies investigating the biological changes during dying and there are no studies prospectively investigating biochemical changes during the dying process.

2. A number of authors postulate a common final dying pathway.

3. Research into the biological changes at the end of life could develop a greater understanding of the dying process. This research would have the potential to significantly impact the care future dying patients receive.